Good
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment with the prescribing information is good. The AI-derived claims are largely supported by the label (e.g., oral tablet formulation, pain relief for acute musculoskeletal conditions, CNS-depression-related mechanism, sedative effects, CNS actions, lack of direct skeletal-muscle relaxation, common/adverse events, and renal-impaired dosage considerations). Some statements are appropriately labeled as absent when not supported by the provided label sections. However, there are inaccuracies in the AI evaluation, notably regarding pregnancy safety information omission, which is actually present in WARNINGS, and several injectable/excipients-related claims that are not supported by the provided label sections.
Category Scores
Accurate Statements
Methocarbamol is formulated as an oral tablet.
Yes; HOW SUPPLIED lists 750 mg tablets.
Methocarbamol is prescribed to treat pain associated with acute musculoskeletal conditions.
Yes; INDICATIONS AND USAGE describes relief of discomfort associated with acute, painful musculoskeletal conditions.
Methocarbamol depresses the central nervous system.
Yes; CLINICAL PHARMACOLOGY indicates mechanism may be due to general CNS depression.
Methocarbamol has sedative effects.
Yes; label notes sedative properties; adverse reactions include drowsiness.
Methocarbamol acts centrally on the central nervous system.
Yes; mechanism described as possibly due to CNS depression.
Methocarbamol does not directly act on skeletal muscles.
Yes; label states it does not directly relax tense skeletal muscles.
Common side effects include drowsiness.
Yes; drowsiness listed among adverse reactions.
Common side effects include dizziness.
Yes; dizziness listed among adverse reactions.
Common side effects include lightheadedness.
Yes; lightheadedness listed among adverse reactions.
Common side effects include nausea.
Yes; nausea listed among adverse reactions.
Less common side effects include blurred vision.
Yes; blurred vision listed among adverse reactions.
Less common side effects include headache.
Yes; headache listed among adverse reactions.
Less common side effects include rash.
Yes; rash listed among adverse reactions.
Serious side effects may include allergic reactions.
Yes; hypersensitivity reactions listed as adverse effects.
Patients with kidney impairment may require dosage adjustments.
Yes; Renally impaired section notes clearance may require dosage adjustments.
Non-pharmacological approaches like physical therapy can be effective in managing muscle spasms.
Partial; Indication notes adjunct to physical therapy.
Unsupported Statements
The injectable solution contains methocarbamol.
Label sections provided describe oral tablet formulation; no injectable formulation is listed.
The injectable solution contains polyethylene glycol.
No injectable ingredients are listed in the provided label sections.
The injectable solution contains water for injection.
No injectable ingredients are listed in the provided label sections.
The oral formulation includes povidone.
Excipient content is not enumerated in the provided label sections.
The oral formulation includes sodium starch glycolate.
Excipient content is not enumerated in the provided label sections.
The oral formulation includes magnesium stearate.
Excipient content is not enumerated in the provided label sections.
Methocarbamol is prescribed to treat muscle spasms.
Indication describes relief of discomfort with acute, painful musculoskeletal conditions, not explicitly 'muscle spasms.'
Cyclobenzaprine is an alternative muscle relaxant.
No such alternatives listed in the provided label sections.
Carisoprodol is an alternative muscle relaxant.
No such alternatives listed in the provided label sections.
Contradictions
Low
AI Statement
Methocarbamol is a muscle relaxant.
Label Reference
INDICATIONS AND USAGE
Important Omissions
Detailed dosage and administration guidance.
Importance:
Moderate
Pregnancy safety details are stated in WARNINGS; the AI evaluation claimed none. This is a material omission by the AI response.
Importance:
High
Hepatic impairment dosage adjustments are not explicitly stated; pharmacokinetic data are provided but explicit dosage adjustment guidance is not.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The majority of claims align with the label; no high-risk safety misstatements identified; some misclassifications regarding pregnancy information in the AI evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Misclassification of muscle relaxant status and incorrect pregnancy-safety omission in the AI evaluation.
Suggested Improvement
Align evaluation with label: indicate indication as relief of pain associated with acute, painful musculoskeletal conditions (not explicitly muscle spasms); confirm absence/presence of injectable formulation and excipient details from the label; accurately cite pregnancy warnings from WARNINGS; avoid asserting excipient content without label support.